Just days after news that Trump was set to select ex-Eli Lilly executive Alex Azar for the US government's top healthcare post, he tweeted the nomination Monday morning. More recently, Azar served in many roles with Eli Lilly and Company, an worldwide pharmaceutical company, where as President of Lilly USA, he oversaw the substantial rise in drug prices while simultaneously serving on the board for the world's largest pharmaceutical lobby, Biotechnology Innovation Organization.
In an October letter, Reps. Azar appears to prefer moving authority to the states over Medicaid. After leaving Lilly as part of an executive shakeup earlier this year, Azar formed a consultancy as he explored "new leadership opportunities", according to an online speaker profile.
A representative for Eli Lilly told CNN in a statement that the company "makes all of its pricing decisions independently and in strict compliance with all laws, regulations and guidelines applicable to our business". Ron Wyden said the president "at every turn. has broken his promises to American families to lower health care costs, expand access and bring down the high price of prescription drugs." Sen. The administration has been working on an executive order but it has yet to be released. If Alex Azar's nomination is confirmed, then Big Pharma's coup d'etat in the health care sphere will be virtually complete. Lamar Alexander, who chairs the Senate health committee. Prior to those postings, he was known as an Associate Independent Counsel for Ken Starr, investigating the Whitewater controversy during Bill Clinton's presidency. He also worked on Bush's 2000 presidential campaign before his first stint at HHS.
The resignation of Tom Price was seen as politically expedient after his spurious usage of private and government aircraft over commercial planes caused an uproar and instigated investigations into the wasteful practice.